Skip to main content
. 2018 Nov 1;9(11):1112. doi: 10.1038/s41419-018-1160-2

Fig. 6. ABT-199 can sensitize non-responders to the combination of a translationally relevant, hexavalent TRAIL receptor agonist IZI1551 and TL32711.

Fig. 6

a Responder cell line MZ18 was treated with combinations of IZI1551 and TL32711. After 24 h, cell death was measured by PI-based flow cytometry. Cell death is shown as increase above untreated controls. Data are means of three independent experiments, with triplicate samples analysed in each experiment. Error bars were omitted for clarity. b MZ18 cells were treated with the combination of IZI1551/TL32711 in the presence or absence of pan-caspase inhibitor zVAD-fmk (50 µM) for 24 h. Cell death was measured by PI-based flow cytometry. Data represent mean ± SEM of three independent experiments. ***p < 0.001 (one-way ANOVA followed by Tukey post hoc test). c Non-responder cell lines remained largely resistant to the combined treatment of IZI1551 and TL32711. d Immunofluorescence-based detection of cytochrome c release. MZ304 cells were treated for 16 h, U343 cells were treated for 24 h (10 ng/ml IZI1551; 1 μM TL32711; 10 μM ABT-199; 50 μM zVAD-fmk). Scale bar 10 µm. Arrowheads indicate cells that released cytochrome c. e Cells were treated with IZI1551 (10 ng/ml) and/or TL32711 (1 µM) in the presence or absence of ABT-199 (5 μM) and zVAD-fmk (50 μM). Cell death was measured after 24 h by PI-based flow cytometry. Data represent mean ± SEM of three independent experiments. ***p < 0.001 (one-way ANOVA followed by Tukey post hoc test). f Graphical summary